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Abstract 40 
Background:  41 
British guidelines recommend that serial acute serum tryptase (acute serum tryptase) measurements are 42 
checked in all adults and a subset of children presenting with anaphylaxis. This is the first study 43 
reporting the clinical utility of acute serum tryptase in a ‘real world’ emergency department (ED) setting 44 
following the publication of the World Allergy Organization criteria for anaphylaxis. 45 
Aims: To (a) assess sensitivity, specificity, positive and negative predictive values (PPV, NPV) of acute 46 
serum tryptase in anaphylaxis (b) determine factors associated with higher acute serum tryptase levels 47 
and (c) audit compliance of acute serum tryptase measurement in the EDs. 48 
Methods: Retrospective electronic search for ED admissions to three acute care hospitals in 49 
Birmingham, UK with anaphylaxis in 2012 using wide search terms followed by scrutiny of electronic 50 
clinical records and application of the WAO diagnostic criteria for anaphylaxis. Patients with an acute 51 
serum tryptase measurement were included in the analysis. 52 
Results: Acute serum tryptase was measured in 141 of 426 (33.1%) cases. Mean time from the onset 53 
of symptoms to the measurement of acute serum tryptase was 4 hours 42 minutes (SD ± 05:03 hours) 54 
and no patients had serial measurements conforming to British guidelines. Acute serum tryptase >12.4 55 
ng/ml (75th centile) was associated with a sensitivity, specificity, PPV and NPV of 28%, 88%, 0.93 and 56 
0.17 respectively. Multiple regression analysis showed that male sex (OR = 2.66 [p=0.003]) and 57 
hypotension (OR=7.08 [p=0.001]) predicted higher acute serum tryptase.  58 
Conclusion:  59 
An acute serum tryptase >12.4 ng/ml in an ED setting carries high PPV and specificity, but poor 60 
sensitivity and NPV.    61 
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Highlights 82 
 83 
What is already known about this topic? 84 
Acute serum tryptase can be raised in anaphylaxis and current British guidelines recommend serial 85 
measurements. Sensitivity and specificity is published from the controlled environment of allergen 86 
challenge but not from the emergency department. 87 
What does this article add to our knowledge? 88 
This British study is the first to document the sensitivity, specificity, positive and negative predictive 89 
value of acute serum tryptase in emergency department anaphylaxis. Acute serum tryptase >12.4 ng/ml 90 
carries a high positive predictive value and specificity but poor sensitivity. 91 
How does this study impact current management guidelines? 92 
Optimal real world sampling of acute serum tryptase is difficult and acute serum tryptase is a poor 93 
biomarker for anaphylaxis. However, acute serum tryptase is useful in some situations to differentiate 94 
anaphylaxis from its mimics and should remain part of anaphylaxis assessment.   95 
5 
 
Introduction 96 
Tryptase is a serine protease released from mast cells during an acute allergic reaction. Acute serum 97 
tryptase measurement is advised in the evaluation of patients with anaphylaxis. (1-2) British guidelines 98 
explicitly recommend that serial blood samples for acute serum tryptase should be taken as soon as 99 
possible after the onset of symptoms, at 1-2 hours following symptom onset and a baseline sample at 100 
least 24 hours after the episode. (1) These timings reflect the half-life of tryptase which is approximately 101 
two hours with levels peaking 1-2 hours after onset and usually returning to baseline within 6-8 hours. 102 
(3-4) The results are not immediately available to the emergency physician and therefore are not part 103 
of the initial evaluation but are used later in the follow-up of these patients at an allergy clinic.  104 
The role for biomarkers of anaphylaxis, acute serum tryptase in particular, is unclear especially as 105 
seemingly severe episodes of anaphylaxis may not be associated with an elevated level (3,5) and vice-106 
versa. Furthermore, there are currently no agreed international criteria for interpretation of acute serum 107 
tryptase in anaphylaxis with respect to a ‘cut off’ or a percentage change from a baseline measurement, 108 
although ≥11.4ng/ml is frequently cited. Given that anaphylaxis in the community is nearly always an 109 
unpredictable event and is dealt with almost exclusively by emergency care providers, we felt it 110 
important to investigate acute serum tryptase in this group of patients. Previous studies investigating 111 
the utility of acute serum tryptase in an ED setting have involved prospective recruitment of patients 112 
with relatively small sample sizes, used different ‘cut off’ levels for interpretation and were carried out 113 
prior to publication of the World Allergy Organization (WAO) diagnostic criteria for anaphylaxis which 114 
now provide us with a unified, agreed definition of anaphylaxis. Moreover, they did not report 115 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). (3,5-7) 116 
Our study is therefore an attempt to evaluate the performance of acute serum tryptase in a ‘real world’ 117 
setting.    118 
We have recently published epidemiological data on 426 cases of anaphylaxis presenting to three EDs 119 
in Birmingham, UK in 2012. (8) Here, we present further data analysis of a subgroup of patients from 120 
the same cohort who had a measurement of acute serum tryptase when they attended the ED. The main 121 
objectives of the study were to: (a) assess sensitivity, specificity, PPV and NPV of acute serum tryptase 122 
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in patients attending the ED, (b) determine factors associated with higher acute serum tryptase levels 123 
and (c) audit compliance of acute serum tryptase measurement as per British guidelines. 124 
125 
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Materials and Methods 126 
This is a retrospective, observational study of patients attending three busy EDs (total admissions in 127 
2012 - 251,215) with anaphylaxis/suspected anaphylaxis in one of the largest National Health Service 128 
(NHS) organizations in the UK (Heart of England NHS Foundation Trust [HEFT]). The catchment area 129 
of the three hospitals in the organization includes East and North Birmingham, Solihull and South 130 
Staffordshire, a population of over 890,000 people. 131 
Patients 132 
All ED attendances are coded using an ‘in-house’ coding system. We carried out an electronic search 133 
of the database of ED attendances using a number of wide-reaching search terms to cover allergic 134 
presentations and retrieved 3516 potential cases of anaphylaxis. The search terms were: ‘Allergic 135 
Reaction’, ‘Anaphylactic Shock’, ‘Anaphylaxis’, ‘Angioedema’, ‘Bite - Insect Non Venom’, ‘Bite - 136 
Insect Venom’, ‘Skin - Allergic Reaction’, ‘Skin - Rash, Other’ and ‘Skin – Urticaria’.  137 
Next, one clinician scrutinized the scanned ED documentation, ambulance sheet, and other electronic 138 
information including clinic records where available. Through retrospective application of the WAO 139 
diagnostic criteria for anaphylaxis (9) to patients’ presenting symptoms, cases of anaphylaxis were 140 
identified and data extracted. When possible, anaphylaxis mimics such as asthma and hereditary 141 
angioedema, among others, were excluded.   142 
We also identified a small control group of patients (for constructing receiver operating characteristic 143 
[ROC] curves) who presented to the ED with allergic symptoms in whom acute serum tryptase 144 
measurement was requested by the admitting physician, but did not fulfill the WAO diagnostic criteria 145 
for anaphylaxis. 146 
In order to ensure the quality and reproducibility of the data extraction, initial data collection from a 147 
number of case notes was jointly performed by two clinicians in order to ensure appropriate inclusion 148 
and exclusion of cases and to improve consistency. Following this, when there was uncertainty from 149 
the first clinician about inclusion or exclusion of potential cases, these cases were jointly reviewed and 150 
discussed with the second clinician at weekly meetings during the data collection phase. When halfway 151 
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through the data collection period, every previously assessed case was reassessed in order to eliminate 152 
bias associated with learned experience. In this reassessment, there were no cases that had been 153 
erroneously included however several had been missed and these were therefore incorporated into the 154 
dataset.  155 
Basic demographic data including age, sex, address and ethnicity, is available for every patient from 156 
the hospital database. Demographic data and data pertaining to symptoms (including time of onset) and 157 
co-morbidities were extracted from the case records of every attendance that fulfilled the inclusion 158 
criteria using a standardized proforma and recorded in a spreadsheet (Microsoft Excel [2007]). Entries 159 
were coded and checked twice by one clinician. Additionally, where patients had been reviewed by an 160 
allergy specialist, clinic records were analyzed to identify causative factors. As per the hospital policy, 161 
all cases of anaphylaxis and suspected anaphylaxis should be referred to the allergy clinic following 162 
discharge from the emergency department. An appointment is offered for allergy specialist review with 163 
18 weeks from the date of referral (with an option of an urgent appointment in specific cases). Cases 164 
were assigned a severity grading according to the ‘Brown grading system’. (10) acute serum tryptase 165 
measurement including the timing of samples, recorded on the electronic hospital database system, was 166 
extracted from the electronic system including the timing of the sample. Laboratory serum tryptase 167 
analysis was undertaken using a fluoroenzyme immunoassay (Immuno CAP-FEIA) on the 168 
ImmunoCAP platform. (Phadia Thermo-Fisher Scientific, Uppsala, Sweden)  169 
Statistical analysis 170 
Data was analyzed using SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 171 
22.0. Armonk, NY: IBM Corp). Data was checked for outliers, skew and kurtosis.  Missing data were 172 
treated as ‘missing at random’. Four outliers were found and when removed skew and kurtosis were 173 
within acceptable levels for a normal distribution (<1.5). Data were analyzed with and without outliers 174 
and results were the same. Therefore, outliers were included in the dataset to ensure representativeness 175 
of the data. The relationships between acute serum tryptase and age and acute serum tryptase and time 176 
from symptom onset to sampling were analyzed using a Pearson’s correlation. Differences in mean 177 
acute serum tryptase levels across groups were analyzed using independent samples t-tests. Where 178 
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homogeneity of variance was significantly different (through inspection of the Levene’s test), the 179 
corrected ‘t value’ and degrees of freedom (df) were used. Due to the large number of t-tests run, alpha 180 
was set at 0.01. All tests were two-tailed. A forced entry multiple regression model was run to 181 
investigate predictors of acute serum tryptase. All predictor variables that were significantly related to 182 
acute serum tryptase were included in the model. A logistic regression was also run to look at variables 183 
that might predict risk of high acute serum tryptase levels. Figures were constructed using GraphPad 184 
Prism version 5.00 for Windows, GraphPad Software, San Diego California USA. The ROC curve was 185 
constructed from the acute serum tryptase measurements from the anaphylaxis group and non-186 
anaphylaxis control group using Prism GraphPad 5.00. Sensitivity, specificity, positive predictive 187 
values (PPV) and negative predictive values (NPV) were calculated at the 25th, 50th and 75th centiles of 188 
acute serum tryptase measurements in the anaphylaxis group.  189 
Data storage and institutional approval 190 
To ensure data protection, data was stored on a physically and digitally secured computer at 191 
Birmingham Heartlands Hospital. The Microsoft Excel document was encrypted and all patient 192 
identifiable information was removed prior to analysis. The project was reviewed by the Research and 193 
Development Department (in HEFT) who verified that formal ethical approval was not required and 194 
then registered with the Clinical Governance Unit. The project required no external funding. 195 
196 
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Results 197 
Study population 198 
The study algorithm is summarized in Figure 1. Of 426 attendances, 141 (33.1%) had an acute serum 199 
tryptase measurement. Demographics of the study sample are summarized in Table 1 and for the entire 200 
cohort in a recent publication by the authors along with extensive epidemiological analysis. (8) In our 201 
cohort of 426 patients, 105 (24.6%) were children (<16 years) and of these children only 6/105 (5.7%) 202 
had a measurement of acute serum tryptase. In children 86% of reactions were attributed to food and 203 
current British guidelines recommend acute serum tryptase measurement in children only in cases of 204 
drug-induced, venom-induced or idiopathic anaphylaxis. (8) The mean age of the group who had acute 205 
serum tryptase measured is higher than the group that did not.  206 
Clinical manifestations  207 
44/141 (31.2%) patients had cardiovascular symptoms or signs, of which 15 (10.6%) had hypotension. 208 
126 (89.3%) had respiratory involvement with 41 (29.1%) having objective evidence of bronchospasm 209 
and 9 (6.4%) evidence of hypoxia. 140 (99.3%) had skin or mucosal involvement, 42 (29.8%) 210 
generalized urticaria, and 87 (61.7%) angioedema. 35 (24.8%) had gastrointestinal involvement.  211 
Acute serum tryptase 212 
Mean acute serum tryptase in the anaphylaxis group was 10.3ng/ml (SD ±10.4). In the control group of 213 
25 patients mean acute serum tryptase was 6.8ng/ml [SD ±5.9]) (t=1.65 df=164 [p=0.10]). In the 214 
anaphylaxis group, acute serum tryptase was raised at or above 11.4ng/ml (a previously accepted ‘cut-215 
off’) in 46 (32.6%) cases. In the control group, 3/25 (12.0%) had an acute serum tryptase ≥11.4ng/ml. 216 
132/141 (93.6% had a recorded time of sampling on the electronic system. Of these, the mean time to 217 
the first acute serum tryptase measurement from onset of symptoms was 4 hours and 42 minutes (SD ± 218 
05:03 hours). There was a weak negative correlation between acute serum tryptase level and time 219 
between symptom onset to sampling (Pearson correlation coefficient -0.19 [p=0.026]) (Figure S1). 220 
There was no statistically significant difference in mean time of sampling in the severe and non-severe 221 
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anaphylaxis groups (t=1.13 df=133 [p=0.26]) and no statistically significant difference in mean time of 222 
sampling across different etiologies. No patients had serial measurements of acute serum tryptase. 223 
23/141 (16.3%) patients had a baseline serum tryptase more than 24 hours after symptom onset although 224 
none of these measurements were raised (≥11.4ng/ml). The median difference (delta) between acute 225 
serum tryptase and baseline tryptase was 115.9% (IQR 26.5 to 238.2). Delta was greater than the 226 
previously quoted cut-off of 135% (11) for 9/23 (39.1%) cases. 13/45 (28.9%) patients with an acute 227 
serum tryptase ≥11.4 had a baseline tryptase measurement and 4/21 (19.0%) patients with acute serum 228 
tryptase ≥20 had a baseline tryptase measurement. All the patients with baseline measurements were 229 
seen in the clinic. There was a statistically significant difference between mean baseline serum tryptase 230 
and acute serum tryptase in the group with severe anaphylaxis (n=10, baseline 4.6ng/ml (SD ± 1.3) vs 231 
acute serum tryptase 19.6ng/ml (SD  ± 16.4) (paired T-test: t=2.921 df=9 [p=0.017]) with a smaller, 232 
non-significant difference in the non-severe anaphylaxis group (n=13, baseline 5.1ng/ml (SD ± 2.0), 233 
acute serum tryptase 9.4ng/ml (SD ± 4.9) (t=2.032 df=12 [p=0.065]). Only one patient in the control 234 
group had a measure of baseline serum tryptase. 235 
A mast cell disorder is considered in the differential diagnosis for all patients with spontaneous 236 
(idiopathic) anaphylaxis. Our clinical service considers a dermatology referral if cutaneous 237 
mastocytosis is suspected and the patient is also referred to a hematology clinic for consideration of 238 
bone marrow studies if the baseline serum tryptase is ≥20 ng/ml. In the whole dataset (those who 239 
presented to ED with anaphylaxis regardless of their attendance in the allergy clinic), 13/45 (28.9%) 240 
patients with an acute serum tryptase ≥11.4ng/ml and 4/21 (19.0%) patients with an acute serum tryptase 241 
≥20ng/ml had a baseline tryptase measurement. Following completion of the study, we wrote to the 242 
family physicians of all those patients with a raised acute serum tryptase (>11.4ng/ml) and no record of 243 
baseline tryptase measurement to request that this be checked and that the report is brought to the 244 
attention of the allergy department if the baseline value is ≥11.4ng/ml, so a diagnosis of an underlying 245 
mast cell disorder could be considered. These additional measurements were not included in the study 246 
analysis. 247 
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Etiology of anaphylaxis 248 
76 (53.9%) patients with an acute serum tryptase measurement were reviewed in person by an allergy 249 
specialist in the secondary care clinic (in HEFT) for a comprehensive clinical evaluation and for further 250 
investigations as deemed necessary. All investigations were complete at the time of record review by 251 
the authors. Idiopathic anaphylaxis was the most common etiology (45/76 cases [59%]) and was twice 252 
as common in females as in males (35/49 [71.4%] vs. 10/27 [37%] respectively (2=7.16, df=1 253 
[p=0.008]). There were 11 (14.5%) cases of food-induced anaphylaxis. In this group, mean acute serum 254 
tryptase was 13.7 (SD ± 10.6) with 6/11 (15.5%) patients having an acute serum tryptase ≥11.4ng/ml 255 
and 3/11 (27.3%) having an acute serum tryptase ≥20ng/ml. There were 15 (19.7%) cases of drug-256 
induced anaphylaxis. In this group, mean acute serum tryptase was 12.6ng//ml (SD ± 15.2) with 5/15 257 
(33.3%) patients having an acute serum tryptase ≥11.4ng/ml and 2/15 (13.3%) having an acute serum 258 
tryptase ≥20ng/ml. There were 45 (59.2%) cases of idiopathic anaphylaxis. In this group, mean acute 259 
serum tryptase was 7.7ng/ml (SD ± 8.3) with 8/45 (17.8%) having an acute serum tryptase ≥11.4ng/ml 260 
and 4/45 (8.9%) having an acute serum tryptase ≥20ng/ml. Idiopathic anaphylaxis was associated with 261 
lower acute serum tryptase levels than anaphylaxis due to drugs and food combined (mean 7.6ng/ml 262 
[SD ± 8.2] vs. 13.2ng/ml [SD ± 13.1] (t=2.26, df=67 [p=0.027]). After thorough evaluation, no patient 263 
with idiopathic anaphylaxis was subsequently found to have indolent mastocytosis. There were no cases 264 
of venom-induced anaphylaxis in patients that had a measurement of acute serum tryptase reflecting the 265 
low frequency of cases in our entire cohort of 426 cases. Further details regarding etiology of 266 
anaphylaxis in the entire cohort (regardless of acute serum tryptase measurement) can be found in our 267 
recent publication.(8) 268 
Children 269 
There were six children (<16 years old) who had a measurement of tryptase. Details are summarized 270 
in Table 2. 271 
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ROC curve 272 
The ROC curve (Figure 2) was generated using acute serum tryptase levels in patients presenting with 273 
anaphylaxis and acute serum tryptase levels in controls as described in the previous section. Data is 274 
summarized in quartiles of acute serum tryptase in Table 3. Higher levels of acute serum tryptase (75th 275 
centile ≥12.4ng/ml) showed high specificity (88.0%) and PPV (0.93) for anaphylaxis but showed poor 276 
sensitivity (27.8%) and NPV (0.17). 277 
Factors associated with higher acute serum tryptase:  278 
Univariate analyses are summarized in Table S1. Acute serum tryptase was higher for patients with 279 
severe anaphylaxis as defined by the Brown grading system (p=0.006), those with hypotension 280 
(p=0.012), those with any cardiovascular symptoms (p=0.009), those who had not self-administered an 281 
epinephrine auto-injector (p=0.002) and male sex (p=0.001). These were entered into a forced entry 282 
multiple regression model. The model was significant (F=8.98 (5,140), p<0.001) and explained 25% of 283 
the variance (R2=.25, adj R2=.22). Hypotension (t-value -3.32 [95% CI -15.59 to -3.94] p=0.001) and 284 
male sex (t-value -3.05 [95% CI -8.33 to -1.77] p=0.003) emerged as significant predictors of a higher 285 
acute serum tryptase level (Table 4). 42/141 (29.8%) patients had a history of asthma but this was not 286 
associated with acute serum tryptase (Table S1). 287 
Predictors of high acute serum tryptase 288 
In order to see whether variables could be used to predict the likelihood of someone having a high or 289 
low acute serum tryptase level, a logistic regression model was constructed. We used a previously 290 
suggested acute serum tryptase of ≥11.4ng/ml as a ‘cut off’ between ‘raised’ and ‘not raised’ acute 291 
serum tryptase as the outcome variable. Variables that were significantly related to acute serum tryptase 292 
levels were entered into the model. This model was again significant (2=29.66, p<0.001) and explained 293 
between 19% and 27% of the variance. Male sex and the presence of hypotension again significantly 294 
predicted increased odds of high acute serum tryptase levels (OR = 2.66 for male sex, OR=7.08 for 295 
hypotension [Table 4]).  296 
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Discussion 297 
This is the first study to investigate the sensitivity and specificity of acute serum tryptase in cases of 298 
anaphylaxis presenting to the ED. It also offers an insight into the real world ED scenario and how these 299 
conditions can influence the utility of such a test.  300 
Anaphylaxis is a clinical diagnosis requiring prompt treatment and acute serum tryptase clearly does 301 
not constitute a part of the acute evaluation and management as results are not available to ED clinicians. 302 
Current British guidelines recommend three serial timed measurements of tryptase (1) and notably in 303 
our cohort this was not met in any patient. Whilst the relatively short timescale between the publication 304 
of these guidelines to our study could be cited as a potential reason for poor adherence, previous UK 305 
Resuscitation Council guidelines (2008) also recommended serial tryptase measurements in the same 306 
manner. (12) Multiple factors contribute to poor adherence: staff knowledge, a busy clinical 307 
environment, a ‘four-hour wait target’ where 95% of patients must be reviewed, diagnosed, treated and 308 
either discharged or admitted within four hours, and early discharge or transfer of patients. Acute serum 309 
tryptase results take several days to become available and thus are not available to ED clinicians who 310 
do not therefore see the benefits of the test. Many patients with milder cases of anaphylaxis do not 311 
require intravenous access or other blood tests and acute serum tryptase measurement is therefore a low 312 
priority task which adds to the workload of an already stretched team. 313 
The time point of acute serum tryptase measurement (mean 4 hours 42 minutes [SD ± 05:03 hours]) 314 
was such that the peak rise may have been missed in some cases. This however reflects a ‘real world’ 315 
clinical scenario since the timing of the acute serum tryptase sample depends on multiple factors 316 
including the rapidity of onset of symptoms, when the patient actually presents to ED, how long it takes 317 
to stabilize the patient before the admitting physician is able to obtain a sample for acute serum tryptase 318 
and other confounding practical variables as stated above. However, Stone et al. reported that although 319 
the acute serum tryptase peaks at 2-3 hours post-exposure, levels can, in some patients, remain elevated 320 
at 50% above baseline for up to 10 hours. (3) Previous studies have shown improved sensitivity of acute 321 
serum tryptase when serial measurements are taken (13-15) but clearly in a busy clinical environment 322 
this may be challenging given the ‘four hour wait target’ in the UK NHS as described above. 323 
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Wongkaewpothong et al. (15) and Brown et al. (16) have reported considerably better sensitivity and 324 
specificity than our study at a lower acute serum tryptase levels (50% and 85% respectively at 3.0ng/ml 325 
and 55% and 93% at 9.0ng/ml respectively) however these were in the context of allergen challenge or 326 
immunotherapy where factors such as timing of the sample and definitive diagnosis of anaphylaxis can 327 
optimize the test. Previous ED based studies of acute serum tryptase measurement have not addressed 328 
the sensitivity and specificity of the test. (3,5-7,17) Here we have for the first-time constructed ROC 329 
curves and generated sensitivity, specificity, PPV and NPV in a ‘real world’ ED setting. Using a ‘cut-330 
off’ of 12.4ng/ml (75th centile), we show a sensitivity of 27.8%, specificity of 88% and PPV and NPV 331 
of 0.93 and 0.17 respectively indicating that acute serum tryptase measurement performs much more 332 
poorly in the ED environment. However, with a high specificity, when the acute serum tryptase is raised, 333 
it is highly likely that the patient has experienced anaphylaxis. Previously, it has been reported that a 334 
≥135% rise (from baseline) in acute serum tryptase is a better predictor of anaphylaxis than an absolute 335 
measurement alone. (11) However, this was only seen in 39% of cases in our study. In our anaphylaxis 336 
cohort, only 23/141 (16.3%) patients had a baseline serum tryptase measurement (and only one in the 337 
control group), so we were unable to construct ROC curves for a percentage change from baseline. Only 338 
28.9% of patients with an acute serum tryptase ≥11.4ng/ml and 19.0% of patients with an acute serum 339 
tryptase ≥20ng/ml had a baseline serum tryptase measurement. Mast cell disorders are considered for 340 
all patients with idiopathic anaphylaxis and are investigated and referred appropriately as described 341 
above. 342 
We explored the factors that predict high acute serum tryptase levels using multiple and logistic 343 
regression models. A forced multiple regression model indicated that the presence of hypotension and 344 
male sex were the two factors that significantly predicted a higher acute serum tryptase. This finding 345 
was supported with a logistic regression analysis showing that male sex and presence of hypotension 346 
significantly increase the probability of having levels of acute serum tryptase over the ‘cut-off’ of 347 
≥11.4ng/ml. The association with hypotension is a finding that is in keeping with previously published 348 
data. (3,5-6) However, the observation that patients with hypotension are seven times more likely to 349 
have a raised acute serum tryptase has not been reported previously (Table 4). Thus hypotension is a 350 
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sensitive marker for an elevated acute serum tryptase. The strong association of severe hypotension and 351 
higher acute serum tryptase is further supported by the high levels seen in patients developing severe 352 
cardiovascular perioperative anaphylaxis during general anesthesia, recently reported by our group (18) 353 
and Mertes et al. (19) 354 
The novel finding that male sex predicts higher acute serum tryptase warrants further investigation 355 
particularly as there is no known sex predisposition with respect to severity. Higher baseline serum 356 
tryptase in males has been reported previously (20-22) which may at least in part explain this 357 
association. Also, rates of idiopathic anaphylaxis in our cohort were lower in males than females (37.0% 358 
vs 71.4%) and idiopathic anaphylaxis was associated with lower acute serum tryptase. Previous studies 359 
have reported that food-induced anaphylaxis does not lead to an elevated acute serum tryptase as often 360 
as other causes. (7,23) However, in this study we found that food-induced anaphylaxis leads to an 361 
elevated acute serum tryptase as often as other causes. This may be related to relatively smaller sample 362 
size, wider confidence intervals as well as the fact that a major comparison group is idiopathic 363 
anaphylaxis. Our finding that use of an epinephrine auto-injector is associated with lower acute serum 364 
tryptase may highlight the importance of early administration of epinephrine in preventing a more 365 
severe systemic response to the allergen and thus preventing a rise in acute serum tryptase. 366 
This study has limitations. Firstly, we had a relatively small sample size, although the total number of 367 
cases in our cohort exceeds previous studies. (3,5-7) Additionally, only about a third of patients 368 
presenting with anaphylaxis had a measurement of acute serum tryptase introducing selection bias 369 
although we have shown that among adults in our study, characteristics between groups are broadly 370 
similar although there is a trend towards more severe cases of anaphylaxis being included. The relatively 371 
small sample size is compounded by the low rates of requests for baseline tryptase measurement. 372 
Secondly, this was a retrospective study but all cases were carefully reviewed with respect to ED and 373 
ambulance crew observations and the sampling time for acute serum tryptase was recorded accurately. 374 
Thirdly, the control group that we used was small (25 patients). In the absence of a better control group 375 
the use of this group of patients was a pragmatic choice, as patients with non-allergic conditions do not 376 
have routine acute serum tryptase measurements. These patients had mucocutaneous findings only and 377 
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therefore did not meet the WAO criteria for anaphylaxis, although it is plausible that treatment may 378 
have prevented some of them developing anaphylaxis.  379 
The role of acute serum tryptase measurement in cases of suspected anaphylaxis remains debated 380 
despite being recommended in British and other national and international guidelines. (1-2) Acute 381 
serum tryptase measurement performs substantially better in the more controlled environments of 382 
allergen challenge and immunotherapy (15,24) than it did in our study although an acute serum tryptase 383 
of >12.4 ng/ml in ED patients does makes the diagnosis of anaphylaxis highly likely. The high 384 
specificity of acute serum tryptase at this ‘cut off’ and its strong association with hypotension makes it 385 
a useful test in specific circumstances to distinguish anaphylaxis from its ‘mimics’. Also, it can be of 386 
use in patients presenting with isolated, severe hypotension (e.g. insect-sting induced anaphylaxis with 387 
hypotension alone, perioperative anaphylaxis, Kounis syndrome etc.) or in special groups such as the 388 
elderly, the visually impaired, those with a learning disability or in cases where there is paucity of 389 
historical or clinical information during assessment in an allergy clinic. Acute serum tryptase is of much 390 
less use in cases of sporadic anaphylaxis in otherwise normal patients where the clinical history yields 391 
the diagnosis. There is preliminary evidence supporting the role for newer biomarkers in anaphylaxis 392 
including chymase, carboxypeptidase and dipeptyl peptidase 1. (25-26) Further studies are required for 393 
investigating the clinical utility of these biomarkers in anaphylaxis.  394 
In conclusion, our data has shown that acute serum tryptase has a high PPV and specificity, and low 395 
sensitivity and NPV in the diagnosis of anaphylaxis presenting to EDs of NHS hospitals in the UK. 396 
Hypotension and male sex were significant predictors of higher acute serum tryptase and there is a 397 
suggestion that the use of an epinephrine auto-injector can prevent a rise in acute serum tryptase. 398 
Furthermore, there was poor compliance with British guidelines with respect to serial acute serum 399 
tryptase measurement in the three EDs included in this study. Serial acute serum tryptase measurements 400 
may be impractical in the vast majority of cases of anaphylaxis which are seen, diagnosed, treated and 401 
discharged from the ED within four hours.  402 
  403 
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Figure legends 480 
Figure 1: Study algorithm. 3516 attendances to the ED during 2012 were identified using an electronic 481 
search of the attendances database using wide search terms. 426 attendances fulfilled the WAO 482 
diagnostic criteria for anaphylaxis. 141 patients had a measurement of acute serum tryptase, and 23 of 483 
these had a baseline tryptase measurement. 76 were followed up in the allergy clinic. 484 
Figure 2. Receiver operating characteristic (ROC) curve. ROC curve showing acute serum tryptase 485 
measurements in patients with anaphylaxis vs control group (patients not fulfilling the WAO diagnostic 486 
criteria for anaphylaxis). Area: 0.58, 95% CI 0.47 – 0.69, p=0.19. Table 3 shows sensitivity, specificity, 487 
negative predictive value (NPV) and positive predictive value (PPV) for acute serum tryptase at 488 
different ‘cut-offs’. 489 
Figure S1. Correlation between acute serum tryptase measurement and time from symptom onset 490 
to sampling. There is a weak negative correlation between acute serum tryptase level and time between 491 
symptom onset to sampling. Pearson correlation coefficient -0.19 (p=0.026). N=132 (9 did not have 492 
recorded timings). 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
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Accompanying tables: 503 
 504 
Anaphylaxis and Clinical Utility of Real World Measurement of Acute Serum Tryptase in UK 505 
Emergency Departments  506 
Buka et al. 507 
  508 
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Table 1. Demographics of the study population 509 
 AT measured 
AT not 
measured Total p-value 
Number of cases of anaphylaxis 141 (33.1%) 285 (66.9%) 426  
Number of severe cases* 56 (39.7%) 89 (31.2%) 145 (34.0%) 0.08 
Sex     
Males 55 (39.0%) 116 (40.7%) 171 (40.1%) 
0.75 
Females 86 (61.0%) 169 (59.3%) 255 (59.9%) 
Mean age  
40.4 
(SD ± 20.2) 
26.7 
(SD ± 21.4) 
31.3 
(SD ± 22.0) 
<0.001 
Mean age of adults (those ≥16y) 41.7 
(SD ± 19.5) 
38.4 
(SD ± 17.9) 
39.8 
(SD ± 18.7) 
0.12 
Patients with asthma 43 (30.4%) 78 (27.4%) 121 (28.4%) 0.57 
 510 
*Brown severity grading (10)  511 
24 
 
Table 2. Children (<16 years old) with anaphylaxis and acute serum tryptase measurements. 2/6 512 
(33.3%) children had AT ≥11.4ng/ml. None had a measurement of baseline tryptase available at the 513 
time of the study. None had hypotension or other evidence of cardiovascular compromise.  514 
Age Sex Severity 
(Brown grading) 
Treated with 
epinephrine 
AT (ng/ml) Causative 
factor 
5 Male Severe Yes 35.5 Nuts 
6 Male Severe Yes 6.05 Milk 
10 Female Severe Yes 3.82 Nuts 
11 Female Not severe No 5.85 Cat 
12 Male Not severe Yes 5.24 Nuts 
12 Male Not severe Yes 12.1 Nuts 
Mean: 9.3    Median: 5.95  
 515 
   516 
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Table 3. Table associated with Figure 2 showing sensitivity, specificity, negative predictive value  517 
 518 
(NPV) and positive predictive value (PPV) for AT at different ‘cut-offs’ according to ROC analysis. 519 
 520 
 521 
 522 
 523 
 524 
  525 
75th centile 
Tryptase cut-off: 12.4ng/ml 
Anaphylaxis Non-anaphylaxis PPV NPV Sensitivity (%) 
Specificity 
(%) 
Tryptase raised 38 3 0.93 0.17 27.8 88.0 Tryptase not raised 104 22 
50th centile 
Tryptase cut-off: 5.4ng/ml 
Anaphylaxis Non-anaphylaxis PPV NPV Sensitivity (%) 
Specificity 
(%) 
Tryptase raised 72 9 0.89 0.19 50.7 64.0 Tryptase not raised 70 16 
25th centile 
Tryptase cut-off: 3.8ng/ml 
Anaphylaxis Non-anaphylaxis PPV NPV Sensitivity (%) 
Specificity 
(%) 
Tryptase raised 107 18 0.86 0.17 75.4 28.0 Tryptase not raised 35 7 
26 
 
Table 4.  Logistic regression analysis showing predictors of acute tryptase. 526 
Predictors Standard Error Wald test p-value Exp (B) 
95% Confidence 
Intervals 
     Lower Upper 
Sex (male) .41 5.64 .02 2.66 1.19 5.95 
Cardiovascular .56 .70 .79 1.16 .39 3.44 
Hypotension .81 5.91 .01 7.08 1.46 34.33 
Brown Grading .49 1.72 .19 .53 .20 1.37 
Use of AAI* 1.16 1.90 .17 .20 .02 1.96 
 527 
*Adrenaline auto-injector 528 
Cox and Snell R2 = .190 529 
Nagelkerke R2=.265 530 
-2 log likelihood = 148.42 531 
 532 
Statistically significant p-values are given in bold 533 
 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
  543 
27 
 
Table S1. Univariate analysis: means (standard deviations) of AT levels across clinical characteristics 544 
Clinical characteristics N (Total = 141) 
Mean (± SD) 
acute tryptase 
t value 
(df) p value 
Sex  14.5 (13.2)   
Male 55 7.7 (6.9) 3.53 0.001 
Female 86  (73.26)  
Ethnicity  10.1 (9.6)   
White British 89 11.0 (11.5) -.45 0.66 
South Asian 39  (126)  
Hypotension     22.0 (17.3)   
Yes 15 8.9 (7.6) 2.87 0.012 
No 126  (14.78)  
Cardiovascular symptoms  14.5 (15.0)   
Yes 44 8.4 (7.6) 2.72 0.009 
No 97  (54.85)  
Respiratory symptoms  9.9 (9.8)   
Yes 126 14.3 (14.4) -1.60 0.12 
No 15  (139)  
Wheeze  10.8 (11.2)   
Yes 41 10.1 (10.1) .35 0.96 
No 100  (139)  
Hypoxia  10.5 (7.5)   
Yes 9 10.3 (10.6) .05 0.96 
No 132  (139)  
Stridor  11.9 (12.9)   
Yes 6 10.3 (10.3) .37 0.71 
No 135  (139)  
Skin/mucosal involvement  10.3 (10.4)   
Yes 140 10.9 n/a n/a 
No 1    
Gastrointestinal symptoms  10.9 (10.2)   
Yes 35 10.1 (10.5) .41 0.69 
No 106  (139)  
Brown grading  8.1 (7.4)   
Mild 85 13.6 (13.1) 2.85 0.006 
Severe 56  (78.17)  
Asthma  8.8 (8.9)   
Yes 42 10.9 (11.0) -1.13 0.26 
No 98  (138)  
Use of ACE-inhibitors  9.4 (6.6)   
Yes 63 10.4 (10.6) -.29 0.77 
No 131  (139)  
Use of Beta Blockers  4.4 (1.3)   
Yes 3 10.5 (10.5) -.99 0.32 
No 138  (139)  
Used epinephrine auto-
injector  4.7 (5.2)   
Yes 12 10.8 (10.6) -3.47 0.002 
No 129 14.5 (13.2) (20.92)  
 545 
28 
 
 546 
Statistically significant p values are given in bold 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
   Table 3 continued 
Clinical characteristics N (Total = 141) 
Mean (± SD)  
acute tryptase 
t-value 
(df) p value 
Administered epinephrine     
Yes 82 10.9 (11.6) .77 0.45 
No 59 9.5 (8.5) (139)  
Administered 2nd epinephrine     
Yes 21 8.5 (8.5) -.85 0.40 
No 120 10.6 (10.7) (139)  
Needed intravenous fluid     
No 37 12.3 (12.2) 1.36 0.18 
Yes 104 9.6 (9.6) (139)  
29 
 
Accompanying figures: 563 
 564 
Anaphylaxis and Clinical Utility of Real World Measurement of Acute Serum Tryptase in UK 565 
Emergency Departments  566 
Buka et al. 567 
 568 
Total population of catchment area  
n=891159 
Emergency department attendances in 2012 
n= 251215 
Attendances identified by search  
n= 3516 
Excluded by search n= 247699 
Attendances fulfilling WAO criteria n= 426 
Excluded n= 3090 
Not meeting WAO criteria n= 3067 
Incomplete records n= 23 
Acute serum tryptase measured n=141 
Acute serum tryptase not measured n=285 
Seen in allergy clinic n= 76 
Baseline tryptase measured n=23 
30 
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